Physician profile
Mark H Nelson
NPI 1417953654
$8,204.44
in general payments reported to CMS, 2019-2025
17 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $930 · 2020: $1,632 · 2021: $4,622 · 2022: $240 · 2023: $514 · 2024: $165 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $6,110.38 | 2019-2021 | |
| Alimera Sciences, INC. | $265.70 | 2019-2022 | |
| Genentech USA, INC. | $215.08 | 2019-2024 | Vabysmo |
| Genentech, INC. | $191.70 | 2022-2023 | Vabysmo, Lucentis |
| Apellis Pharmaceuticals, INC. | $182.44 | 2022-2023 | Syfovre |
| Notal Vision, INC. | $148.44 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $132.90 | 2019-2021 | |
| Alcon Vision LLC | $132.28 | 2023-2024 | Constellation |
| Mallinckrodt Hospital Products INC. | $119.62 | 2020 | |
| Astellas Pharma US INC | $115.57 | 2023 | |
| Allergan, INC. | $109.11 | 2019 | |
| Oyster Point Pharma, INC. | $103.75 | 2023 | Tyrvaya |
| Dompe US, INC. | $101.38 | 2025 | Oxervate |
| Thrombogenics, INC. | $100.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.51 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $57.48 | 2019 | |
| Bausch & Lomb Americas INC. | $39.38 | 2023 | Visudyne |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.